{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:08:36Z","timestamp":1782846516769,"version":"3.54.5"},"reference-count":60,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Cancer"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Small cell lung cancer (SCLC) is a challenging disease to treat due to rapid progression, development of chemoresistance, and discrepancies in outcomes between real-world data and clinical trials. There is a lack of comprehensive analyses in other studies with regard to intermediate events and the treatment process, such as treatment decisions, progression of disease, and the occurrence of adverse events (AEs) over time.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n The aim of this study was to apply advanced statistical methods to a longitudinal SCLC dataset in order to identify factors of importance for the risk of AEs and for survival.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Treatment pathways of 421 patients with SCLC collected from Karolinska University Hospital, located in Stockholm, Sweden, between 2016 and 2022, were analyzed with data-driven modeling. The analysis focused on the impact of dose adjustment on AEs, including neutropenia, by estimating odds ratios (ORs) using Bayesian mixed effects modeling. Covariates\u2019 effects on Eastern Cooperative Oncology Group performance status (ECOG PS) deterioration and early discontinuation of chemotherapy with cause-specific hazard ratios (csHR) were explored using competitive risk models. This approach was applied to patient cohorts receiving combinatorial first-line platinum\/etoposide and second-line platinum\/etoposide or platinum\/irinotecan.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n At the end of the first-line treatment, most patients exhibited tumor regression (n=167). Patients with neutropenia had longer overall survival (hazard ratio 0.70, 95% CI 0.53-0.92). Higher etoposide dose levels were associated with subsequent occurrences of AEs (OR 5.97, 95% CI 1.41-30.5) and neutropenia (OR 3.55, 95% CI 1.03-13.3). Dose adjustment did not affect overall survival if the patient completed the 4-dose regimen treatment. With regard to second-line therapy, fewer patients completed 4 treatment cycles, and the most common reason for early discontinuation was tumor progression (n=72, 58%). Male patients (n=118) experienced fewer AEs and better first-line treatment response compared to females (csHR 0.51, 95% CI 0.25-0.90). High-risk patients (defined as ECOG PS 2\u20103 or age >75 years) with early discontinuation of therapy had survival outcomes similar to those who did not receive any therapy.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Our results indicate that first-line therapies may benefit from more individualized dosing strategies. It would also be beneficial to assess the risk-benefit of treating specific subgroups, including patients receiving second-line therapy. Real-world data proved beneficial for studying therapy response and risk-benefit of treating patient groups that are underrepresented in clinical trials.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/84042","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:15:07Z","timestamp":1772554507000},"page":"e84042-e84042","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Evidence of Treatment Outcomes in Small Cell Lung Cancer: A Bayesian Mixed Effects and Competitive Risk Approach"],"prefix":"10.2196","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3398-2296","authenticated-orcid":false,"given":"Luca","family":"Marzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5127-0006","authenticated-orcid":false,"given":"Asaf","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8218-4306","authenticated-orcid":false,"given":"Adam S","family":"Darwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8393-560X","authenticated-orcid":false,"given":"Luigi","family":"De Petris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9058-0982","authenticated-orcid":false,"given":"Salomon","family":"Tendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9941-9172","authenticated-orcid":false,"given":"Rolf","family":"Lewensohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3416-4535","authenticated-orcid":false,"given":"Jayanth","family":"Raghothama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1126-3781","authenticated-orcid":false,"given":"Sebastiaan","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"10","key":"R1","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1158\/1078-0432.CCR-14-2958","article-title":"Small cell lung cancer: will recent progress lead to improved outcomes?","volume":"21","author":"Pietanza","journal-title":"Clin Cancer Res"},{"issue":"3","key":"R2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/14728214.2020.1798929","article-title":"Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors","volume":"25","author":"Reddy","journal-title":"Expert Opin Emerg Drugs"},{"issue":"23","key":"R3","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","journal-title":"N Engl J Med"},{"issue":"12","key":"R4","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/oncolo\/oyae234","article-title":"Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer","volume":"29","author":"Shaw","journal-title":"Oncologist"},{"issue":"8","key":"R5","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.70289","article-title":"Real\u2010world response and survival outcomes and treatment patterns in patients with extensive stage small\u2010cell lung cancer receiving third\u2010line treatment","volume":"8","author":"Bar","journal-title":"Cancer Rep"},{"issue":"7","key":"R6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","journal-title":"Ann Oncol"},{"issue":"4","key":"R7","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1080\/0284186X.2019.1711165","article-title":"Treatment patterns and survival outcomes for small-cell lung cancer patients \u2013 a Swedish single center cohort study","volume":"59","author":"Tendler","journal-title":"Acta Oncol"},{"issue":"13","key":"R8","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.ejca.2014.06.002","article-title":"Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials","volume":"50","author":"Ardizzoni","journal-title":"Eur J Cancer"},{"issue":"6","key":"R9","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.21037\/jtd-20-3034","article-title":"Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review","volume":"13","author":"Johal","journal-title":"J Thorac Dis"},{"issue":"8","key":"R10","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13909","article-title":"Exploring the discrepancies between clinical trials and real-world data: a small-cell lung cancer study","volume":"17","author":"Marzano","journal-title":"Clin Transl Sci"},{"issue":"5","key":"R11","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/cpt.659","article-title":"Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future","volume":"101","author":"Darwich","journal-title":"Clin Pharmacol Ther"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-033020-113257","article-title":"Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy","volume":"61","author":"Darwich","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"7","key":"R13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219622","article-title":"Real-world effectiveness and tolerability of small-cell lung cancer (SCLC) treatments: A systematic literature review (SLR)","volume":"14","author":"Povsic","journal-title":"PLOS ONE"},{"issue":"1","key":"R14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3390\/curroncol28010036","article-title":"Real world analysis of small cell lung cancer patients: prognostic factors and treatment outcomes","volume":"28","author":"Moser","journal-title":"Curr Oncol"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1634","article-title":"1540P Real-world analysis of outcomes of first-line chemo-immunotherapy in patients with extensive disease small cell lung cancer (ED-SCLC)","volume":"33","author":"Zellweger","journal-title":"Ann Oncol"},{"issue":"9","key":"R16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41571-019-0250-0","article-title":"The era of alternative designs to connect randomized clinical trials and real-world data","volume":"16","author":"Derksen","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"R17","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/cpt.2565","article-title":"The current landscape and emerging applications for real-world data in diagnostics and clinical decision support and its impact on regulatory decision making","volume":"112","author":"Baumfeld Andre","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"R18","first-page":"15","volume":"28","author":"Schurman","journal-title":"Appl Clin Trials"},{"issue":"4","key":"R19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40801-021-00266-3","article-title":"Current status, challenges, and future perspectives of real-world data and real-world evidence in Japan","volume":"8","author":"Hiramatsu","journal-title":"Drugs Real World Outcomes"},{"issue":"1","key":"R20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40290-022-00456-6","article-title":"Real-world evidence: a primer","volume":"37","author":"Dang","journal-title":"Pharmaceut Med"},{"issue":"1","key":"R21","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1089-4","article-title":"Studying complexity in health services research: desperately seeking an overdue paradigm shift","volume":"16","author":"Greenhalgh","journal-title":"BMC Med"},{"issue":"2","key":"R22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.2000.18.2.395","article-title":"Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council multicenter randomized trial","volume":"18","author":"Thatcher","journal-title":"J Clin Oncol"},{"issue":"28","key":"R23","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1200\/JCO.2009.23.1548","article-title":"Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer","volume":"27","author":"Socinski","journal-title":"J Clin Oncol"},{"issue":"16","key":"R24","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1200\/JCO.2009.25.0654","article-title":"Basic concepts and methods for joint models of longitudinal and survival data","volume":"28","author":"Ibrahim","journal-title":"J Clin Oncol"},{"issue":"5","key":"R25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s42256-019-0048-x","article-title":"Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead","volume":"1","author":"Rudin","journal-title":"Nat Mach Intell"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1016\/j.artmed.2021.102060","article-title":"Machine learning in oral squamous cell carcinoma: current status, clinical concerns and prospects for future \u2013 a systematic review","volume":"115","author":"Alabi","journal-title":"Artif Intell Med"},{"issue":"28","key":"R27","doi-asserted-by":"publisher","first-page":"6344","DOI":"10.1002\/sim.9186","article-title":"A Bayesian approach for event predictions in clinical trials with time-to-event outcomes","volume":"40","author":"Aubel","journal-title":"Stat Med"},{"issue":"1","key":"R28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/sim.7134","article-title":"A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles","volume":"36","author":"Yin","journal-title":"Stat Med"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2021.106265","article-title":"Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model","volume":"102","author":"Zhao","journal-title":"Contemp Clin Trials"},{"issue":"22","key":"R30","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1002\/sim.1572","article-title":"Measuring explained variation in linear mixed effects models","volume":"22","author":"Xu","journal-title":"Stat Med"},{"issue":"4","key":"R31","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2307\/2529876","volume":"38","author":"Laird","journal-title":"Biometrics"},{"issue":"3","key":"R32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40264-023-01380-7","article-title":"An overview of regression models for adverse events analysis","volume":"47","author":"Coz","journal-title":"Drug Saf"},{"issue":"8","key":"R33","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/1078-0432.CCR-11-2097","article-title":"The use and interpretation of competing risks regression models","volume":"18","author":"Dignam","journal-title":"Clin Cancer Res"},{"issue":"11","key":"R34","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","journal-title":"J Clin Oncol"},{"issue":"1","key":"R35","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-09034-6","article-title":"Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis","volume":"21","author":"Jiang","journal-title":"BMC Cancer"},{"issue":"7","key":"R36","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00228-008-0493-7","article-title":"How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach","volume":"64","author":"Ogungbenro","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"R37","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/sam.11348","article-title":"Random forest missing data algorithms","volume":"10","author":"Tang","journal-title":"Stat Anal Data Min"},{"issue":"6","key":"R38","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/aje\/kwt312","article-title":"Comparison of random forest and parametric imputation models for imputing missing data using MICE: a CALIBER study","volume":"179","author":"Shah","journal-title":"Am J Epidemiol"},{"key":"R39","doi-asserted-by":"crossref","unstructured":"Harrell FE . Cox proportional hazards regression model. In: Regression Modeling Strategies. Springer; 2015:475-519. Springer Series in Statistics. [doi: 10.1007\/978-3-319-19425-7_20]","DOI":"10.1007\/978-3-319-19425-7_20"},{"key":"R40","doi-asserted-by":"crossref","unstructured":"Suchmacher M Geller M . Chapter 2: disease frequency measures. In: Practical Biostatistics: A Step-by-Step Approach for Evidence-Based Medicine. 2nd ed. Academic Press; 2021:9-15. [doi: 10.1016\/B978-0-323-90102-4.00017-5]","DOI":"10.1016\/B978-0-323-90102-4.00017-5"},{"issue":"3","key":"R41","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/j.0006-341X.2004.00224.x","article-title":"Bayesian multivariate logistic regression","volume":"60","author":"O\u2019Brien","journal-title":"Biometrics"},{"issue":"1","key":"R42","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1541-0420.2005.00408.x","article-title":"A mixed-effects regression model for longitudinal multivariate ordinal data","volume":"62","author":"Liu","journal-title":"Biometrics"},{"issue":"7","key":"R43","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s40265-018-0909-3","article-title":"Chemotherapy-induced neutropenia as a prognostic and predictive marker of outcomes in solid-tumor patients","volume":"78","author":"Kasi","journal-title":"Drugs (Abingdon Engl)"},{"issue":"3","key":"R44","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00228-023-03451-1","article-title":"Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer","volume":"79","author":"Miyagi","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"R45","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1158\/1078-0432.CCR-15-1295","article-title":"Optimal dosing for targeted therapies in oncology: drug development cases leading by example","volume":"22","author":"Sachs","journal-title":"Clin Cancer Res"},{"issue":"2","key":"R46","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1023\/a:1010639201787","article-title":"Body surface area as a determinant of pharmacokinetics and drug dosing","volume":"19","author":"Sawyer","journal-title":"Invest New Drugs"},{"issue":"3","key":"R47","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3233\/CBM-160580","article-title":"Prognostic significance of serum LDH in small cell lung cancer: a systematic review with meta-analysis","volume":"16","author":"Zhang","journal-title":"Cancer Biomark"},{"issue":"4","key":"R48","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1200\/JCO.2005.03.171","article-title":"Influence of sex on toxicity and treatment outcome in small-cell lung cancer","volume":"23","author":"Singh","journal-title":"J Clin Oncol"},{"issue":"33","key":"R49","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1200\/JCO.2016.67.7088","article-title":"Enrollment trends and disparity among patients with lung cancer in national clinical trials, 1990 to 2012","volume":"34","author":"Pang","journal-title":"J Clin Oncol"},{"issue":"4","key":"R50","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/annonc\/mdl178","article-title":"The illness trajectory of elderly cancer patients across cultures: SIOG position paper","volume":"18","author":"Surbone","journal-title":"Ann Oncol"},{"issue":"5","key":"R51","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1200\/CCI.20.00177","article-title":"Next generation of central cancer registries","volume":"5","author":"Wormeli","journal-title":"JCO Clin Cancer Inform"},{"issue":"9","key":"R52","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ejca.2013.11.040","article-title":"Completeness and timeliness: cancer registries could\/should improve their performance","volume":"51","author":"Zanetti","journal-title":"Eur J Cancer"},{"issue":"5","key":"R53","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/pds.3948","article-title":"Effectiveness of bevacizumab exposure beyond disease progression in patients with non-small-cell lung cancer: analyses of the ARIES observational cohort study","volume":"25","author":"Leon","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"14","key":"R54","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","journal-title":"N Engl J Med"},{"issue":"22","key":"R55","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","journal-title":"N Engl J Med"},{"issue":"4","key":"R56","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/cpt.2838","article-title":"Multistate pharmacometric model to define the impact of second-line immunotherapies on the survival outcome of the IMpower131 study","volume":"113","author":"Krishnan","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"R57","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/psp4.12693","article-title":"Multistate model for pharmacometric analyses of overall survival in HER2\u2010negative breast cancer patients treated with docetaxel","volume":"10","author":"Krishnan","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"R58","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1111\/bcp.14614","article-title":"Dose individualisation in oncology using chemotherapy-induced neutropenia: example of docetaxel in non-small cell lung cancer patients","volume":"87","author":"Lombard","journal-title":"Br J Clin Pharmacol"},{"key":"R59","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115476","article-title":"Integrated modeling of biomarkers, survival and safety in clinical oncology drug development","volume":"216","author":"Liu","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"R60","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-023-00317-1","article-title":"Explainable deep learning for tumor dynamic modeling and overall survival prediction using Neural-ODE","volume":"9","author":"Laurie","journal-title":"NPJ Syst Biol Appl"}],"container-title":["JMIR Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cancer.jmir.org\/2026\/1\/e84042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:18:12Z","timestamp":1782843492000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancer.jmir.org\/2026\/1\/e84042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":60,"URL":"https:\/\/doi.org\/10.2196\/84042","relation":{},"ISSN":["2369-1999"],"issn-type":[{"value":"2369-1999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"v12i10e84042"}}